SPX4,207.27-2.97 -0.07%
DIA333.71+0.51 0.15%
IXIC12,779.91-74.89 -0.58%

BRIEF-Marinus Pharmaceuticals Announces U.S. Commercial Launch Of Ztalmy For Seizures Associated With Cdkl5 Deficiency Disorder

BRIEF-Marinus Pharmaceuticals Announces U.S. Commercial Launch Of Ztalmy For Seizures Associated With Cdkl5 Deficiency Disorder

Reuters · 07/28/2022 07:39
BRIEF-Marinus Pharmaceuticals Announces U.S. Commercial Launch Of Ztalmy For Seizures Associated With Cdkl5 Deficiency Disorder

- Marinus Pharmaceuticals Inc MRNS:

  • MARINUS PHARMACEUTICALS ANNOUNCES U.S. COMMERCIAL LAUNCH OF ZTALMY® (GANAXOLONE) FOR SEIZURES ASSOCIATED WITH CDKL5 DEFICIENCY DISORDER

Source text for Eikon: ID:

Further company coverage: MRNS


((Reuters.Briefs@thomsonreuters.com;))